The rising cost of Phase 3 drug trials means the cost of bringing a new drug to market is between 4-8 Billion dollars. Inevitably this is going to raise the costs of new drugs to already overstretched health economies. Will this mean that only the rich or those in rich countries can afford to have new drugs (before their patent expires) ?